jeudi 30 avril 2020

Onco Actu du 30 avril 2020


4.9 DÉP., DIAG. & PRONO. - SEIN



Kinase Fusions in ESR1 Wild-Type Metastatic Breast Cancer [ESMO]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA approves niraparib for first-line maintenance of advanced ovarian cancer [FDA]










U.S. FDA gives broader approval to GSK's Zejula for ovarian cancer [Reuters]











GSK widens the market for Zejula as FDA signs off on the PARP inhibitor for use in ovarian cancer patients without BRCA mutations [EndPoints]











FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status [GSK]











5.9.12 AACR - BIOPSIES LIQUIDES



Pan-Cancer Screening Tests Report First Performance Numbers in Undiagnosed Cohorts [Genome Web]











First study of multicancer blood test to screen for cancer guide intervention [Johns Hopkins]











5.9.3 AACR - MÉLANOME



AACR 2020: Charles Sawyers Featured Discussant in Opening Plenary [Memorial Sloan Kettering Cancer Center]